Emerging evidence suggests that the AHR is a novel regulator of nonalcoholic fatty liver disease, and its activation can induce lipid oxidation and lipogenic pathways [33,34]. The gene discussed is AHR; the disease is metabolic dysfunction-associated steatotic liver disease.